Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nautilus Biotechnology Inc

NAUT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$0.89

▲ +0.22%

Market Cap $113.51M · Vol 208.86K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$113.51M

Micro Cap

Div Yield

N/A

EPS Growth

-7.45%

YoY

RSI (14)

8.95

Momentum

Beta

0.84

vs Market

52W High

$4.30

79.26% below

52W Low

$0.63

41.59% above

Volume

208.86K

Avg 245.10K

P/B

1.57

Price-to-book

ROE

N/A

Return on equity

Free Float

57.93%

Public shares

Shariah Compliance8 STANDARDS

✗ Nautilus Biotechnology Inc (NAUT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NAUT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.90%

-49.03%

-65.95%

-59.27%

YTD

-54.26%

+23.58%

-71.13%

-88.32%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-59,001,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-27.20% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.57
P/FCF	N/A
EPS Growth	-7.45%
Outstanding Shares	127.26M

Technical Indicators

50-Day SMA	$1.70
200-Day SMA	$2.22
RSI (14)	8.95
Beta	0.84
52-Week High	$4.30
52-Week Low	$0.63

Volume Today	208.86K
Avg Daily Volume (30D)	245.10K
Relative Volume	0.85x
Volatility (10D)	48.67
Volatility (30D)	110.89
Free Float	57.93%

Analyst Consensus

STRONG BUY

Current Price $0.89

Mean Target $4.00

52W Low$0.63 52W High$4.30

Current

Target

$0.63 $4.30

Current Analyst target

+348.43% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00W7G4MV9

ISINUS63909J1088

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.